QNRX

Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX) | Rumor.io

Quoin Pharmaceuticals

QNRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,338

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.01

Market capitalization10.6M

Earnings per share-4.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-15.8M

Social

What share of all stock conversation is about QNRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 31

Quoin Pharmaceuticals, Ltd. (QRX003) has achieved statistical significance in a pivotal Phase 2/3 trial, with 4/6 (66.7%) patients experiencing ≥1-grade IGA improvement, and key secondary endpoint significant at p=0.0070.
The company has secured enough funding to potentially extend its runway into 2029, and has several potential catalysts coming up over the next few weeks, including topline data and potential approval in 2028.
QRX003's valuation is around $50M, with the company accounting for pre-funded warrants, and the US addressable drug market is roughly $150–300M/year, with potential for $300–500M+ globally if QRX003 achieves strong penetration and orphan-level pricing.

Generated by AI

Sentiment

Of the messages about QNRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	88.89% -4.16	88.79% +13.47
Bearish	—	0% 0	11.11% +4.16	11.21% -13.47

Bullish· Aug 28

$QNRX has seen a significant increase in volume, with a notable spike of 27.9M shares, suggesting strong market interest.
The company's market cap has jumped 197% in a day, indicating a substantial increase in investor confidence and valuation.
With a low float of 1.8M shares, $QNRX is poised for potential price manipulation, which could lead to a significant increase in value.

Bearish· Aug 28

Quoin Pharmaceuticals, Ltd. ($QNRX) has a history of offering shares at prices that significantly fall after the offering, as seen in the 2025 shares offering and comparison to shares prices.
The company's decision to offer shares at $4.88 is considered poor management, with some questioning what the company was thinking when making this decision.
The stock has seen a significant decline, with some users predicting it will continue to drop, potentially reaching as low as the $4.88 financing price, and has already fallen 30% from an alert.

Generated by AI

Topics

Of the messages about QNRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	23.21%	14.01%
Technical Analysis	—	100%	30.36%	30.78%
Analysts	—	0%	0%	27.62%
Macro	—	0%	44.64%	27.53%
Earnings	—	0%	1.79%	0.06%
Controversies	—	0%	0%	0%

Announcements· Aug 28

Quoin Pharmaceuticals ($QNRX) shares surged 61.95% after the company announced positive interim data from the Phase 2/3 study of QRX003 in Netherton Syndrome.
The company also announced a private placement of up to $50 million, with $30.8 million upfront and the option to receive up to $19.2 million more if warrants are exercised.
Quoin Pharmaceuticals reported that the first six patients to complete 12 weeks of treatment in the study met the pre-specified alpha-adjusted target for the primary endpoint with statistical significance, and also showed itch reduction and no serious adverse events.

Technical Analysis· Nov 11

$QNRX is forming an ascending wedge in pre-market, requiring a pivot over trend resistance for potential entries.
A MACD cross and rising RSI on the 5-minute chart suggest buying opportunities for $QNRX.
$QNRX has a significant wall of resistance at $13.40, and needs to clear $16 to overcome resistance in the $13-14 range.

Generated by AI

Community

Of the messages about QNRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	10.19%	36.05%
Newcomers	—	100%	89.81%	63.95%

Regulars· Aug 28

$QNRX has reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome, a rare genetic disorder.
Quoin Pharmaceuticals has announced a private placement financing of up to $50.0 million, which will be used for further research and development of its treatments.
The company's market capitalization has increased, making it a potential candidate for a price increase, with some analysts predicting a rise to $8.75 or $9.5 per share.

Newcomers· Aug 31

The company has secured $50M in funding, which will allow them to potentially extend their runway into 2029, and they have several potential catalysts coming up over the next few weeks.
The interim results of the pivotal Phase 2/3 trial showed that the primary endpoint was hit with statistical significance, and key secondary endpoint was also significant, with a 66.7% improvement in ≥1-grade IGA improvement.
The valuation of the company is low, with an enterprise value of ~zero, and the stock price is attractive, with a post-raise cash pro forma of ≈ $38–40M, funded into 2H 2029.

Generated by AI

This New Video Explores the Daily Realities of Raising a Child with Netherton Syndrome, and Its Impact on the Whole FamilyASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sext

20d agoYahoo Finance Singapore

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN,

21d agouk.finance.yahoo.com

Quoin in line for priority review voucher if rare paediatric drug approved

Quoin has now received two rare paediatric disease designations for its lead asset QRX003.

21d agoYahoo Finance

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

22d agoYahoo! Finance Canada

Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases

28d agoInvesting.com

Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs

28d agoInvesting.com

Also Discussed

Investors talking about QNRX also mention

#	Name	Attention
1	Boqii Holding LimitedBQ	0%0
2	Addentax Group Corp.ATXG	0%0
3	Comera Life Sciences Holdings Inc.CMRA	0%0
4	Genenta Science S.p.A. Sponsored ADRGNTA	0%0
5	BWV - Blue Water Vaccines, Inc.	——
6	MHUA - Meihua International Medical Technologies Co., Ltd.	——
7	Virax Biolabs Group Ltd.VRAX	0%+0
8	Intelligent Living Application Group Inc.ILAG	0%new
9	Revelation Biosciences Inc.REVB	0%0
10	MGAM - Mobile Global Esports Inc.	——

Quoin Pharmaceuticals, Ltd. American Depositary Shares

Healthcare
Biotechnology

Quoin Pharmaceuticals, Ltd. American Depositary Shares are a depositary security representing ownership in Quoin Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases. The company’s current programs center on dermatology and other uncommon conditions, including treatments under study for Netherton syndrome, recessive dystrophic epidermolysis bullosa, peeling skin syndrome, SAM syndrome, ichthyosis, and scleroderma. Quoin Pharmaceuticals operates in the biotechnology and specialty drug segment, where its work is aimed at advancing targeted therapies for patient populations with limited treatment options. Its American Depositary Shares provide investors with access to the company’s equity through a U.S.-traded instrument, while the underlying business remains centered on research, development, and potential commercialization of orphan-disease therapies.

Website

Location

42127 Pleasant Forest Court

Ashburn, VA, 20148-7349

United States

Social

What share of all stock conversation is about QNRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 31

Quoin Pharmaceuticals, Ltd. (QRX003) has achieved statistical significance in a pivotal Phase 2/3 trial, with 4/6 (66.7%) patients experiencing ≥1-grade IGA improvement, and key secondary endpoint significant at p=0.0070.
The company has secured enough funding to potentially extend its runway into 2029, and has several potential catalysts coming up over the next few weeks, including topline data and potential approval in 2028.
QRX003's valuation is around $50M, with the company accounting for pre-funded warrants, and the US addressable drug market is roughly $150–300M/year, with potential for $300–500M+ globally if QRX003 achieves strong penetration and orphan-level pricing.

Generated by AI

Sentiment

Of the messages about QNRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	88.89% -4.16	88.79% +13.47
Bearish	—	0% 0	11.11% +4.16	11.21% -13.47

Bullish· Aug 28

$QNRX has seen a significant increase in volume, with a notable spike of 27.9M shares, suggesting strong market interest.
The company's market cap has jumped 197% in a day, indicating a substantial increase in investor confidence and valuation.
With a low float of 1.8M shares, $QNRX is poised for potential price manipulation, which could lead to a significant increase in value.

Bearish· Aug 28

Quoin Pharmaceuticals, Ltd. ($QNRX) has a history of offering shares at prices that significantly fall after the offering, as seen in the 2025 shares offering and comparison to shares prices.
The company's decision to offer shares at $4.88 is considered poor management, with some questioning what the company was thinking when making this decision.
The stock has seen a significant decline, with some users predicting it will continue to drop, potentially reaching as low as the $4.88 financing price, and has already fallen 30% from an alert.

Generated by AI

Topics

Of the messages about QNRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	23.21%	14.01%
Technical Analysis	—	100%	30.36%	30.78%
Analysts	—	0%	0%	27.62%
Macro	—	0%	44.64%	27.53%
Earnings	—	0%	1.79%	0.06%
Controversies	—	0%	0%	0%

Announcements· Aug 28

Quoin Pharmaceuticals ($QNRX) shares surged 61.95% after the company announced positive interim data from the Phase 2/3 study of QRX003 in Netherton Syndrome.
The company also announced a private placement of up to $50 million, with $30.8 million upfront and the option to receive up to $19.2 million more if warrants are exercised.
Quoin Pharmaceuticals reported that the first six patients to complete 12 weeks of treatment in the study met the pre-specified alpha-adjusted target for the primary endpoint with statistical significance, and also showed itch reduction and no serious adverse events.

Technical Analysis· Nov 11

$QNRX is forming an ascending wedge in pre-market, requiring a pivot over trend resistance for potential entries.
A MACD cross and rising RSI on the 5-minute chart suggest buying opportunities for $QNRX.
$QNRX has a significant wall of resistance at $13.40, and needs to clear $16 to overcome resistance in the $13-14 range.

Generated by AI

Community

Of the messages about QNRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	10.19%	36.05%
Newcomers	—	100%	89.81%	63.95%

Regulars· Aug 28

$QNRX has reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome, a rare genetic disorder.
Quoin Pharmaceuticals has announced a private placement financing of up to $50.0 million, which will be used for further research and development of its treatments.
The company's market capitalization has increased, making it a potential candidate for a price increase, with some analysts predicting a rise to $8.75 or $9.5 per share.

Newcomers· Aug 31

The company has secured $50M in funding, which will allow them to potentially extend their runway into 2029, and they have several potential catalysts coming up over the next few weeks.
The interim results of the pivotal Phase 2/3 trial showed that the primary endpoint was hit with statistical significance, and key secondary endpoint was also significant, with a 66.7% improvement in ≥1-grade IGA improvement.
The valuation of the company is low, with an enterprise value of ~zero, and the stock price is attractive, with a post-raise cash pro forma of ≈ $38–40M, funded into 2H 2029.

Generated by AI

Quoin Pharmaceuticals

Social

Aug 31

Bullish· Aug 28

Bearish· Aug 28

Announcements· Aug 28

Technical Analysis· Nov 11

Regulars· Aug 28

Newcomers· Aug 31

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin in line for priority review voucher if rare paediatric drug approved

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases

Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs

Also Discussed

Quoin Pharmaceuticals, Ltd. American Depositary Shares

Company Information

Location

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin in line for priority review voucher if rare paediatric drug approved

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases

Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs

Also Discussed

Social

Aug 31

Bullish· Aug 28

Bearish· Aug 28

Announcements· Aug 28

Technical Analysis· Nov 11

Regulars· Aug 28

Newcomers· Aug 31